6533b829fe1ef96bd128abb6
RESEARCH PRODUCT
Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover
Paul VaseyF. De BraudCarmen LoquaiLuc ThomasEnrique EspinosaWim H. J. KruitRobert M. ConryR. IsaacsCaroline DutriauxVirginia FerraresiBrigitte DrénoJoseph KergerThierry LesimpleA. MarkivskyyClaus GarbeJ.-j. GrobArmin SchuelerC. RobertCéleste LebbéBernard Guillotsubject
0301 basic medicineOncologyNeuroblastoma RAS viral oncogene homologmedicine.medical_specialtybusiness.industryMelanomaHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicinePimasertibIn patientDacarbazine - DTICOpen labelbusinessyear | journal | country | edition | language |
---|---|---|---|---|
2016-10-01 | Annals of Oncology |